Abstract: Disclosed herein are novel synthetic polypeptides and uses thereof in the preparation of liposomes. According to embodiments of the present disclosure, the synthetic polypeptide comprises a membrane lytic motif, a masking motif, and a linker configured to link the membrane lytic motif and the masking motif. The linker is cleavable by a stimulus, such as, light, protease, or phosphatase. Once being coupled to a liposome, the exposure to the stimulus cleaves the linker that results in the separation of the masking motif from the membrane lytic motif, which in turn exerts membrane lytic activity on the liposome that leads to the collapse of the intact structure of the liposome, and releases the agent encapsulated in the liposome to the target site. Also disclosed herein are methods of diagnosing or treating a disease in a subject by use of the present liposomes.

Abstract: The present disclosure relates to a novel class of anti-TNF? monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNF? IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNF? monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Abstract: Disclosed herein are substrates and/or inhibitors of endo-O-sulfatase 1 (Sulf-1). According to some embodiments, the substrates and/or inhibitors of Sulf-1 are compounds of formula (I) or (II), In formula (I) or (II), n is 2 or 3; X is methylene, O, or N; R1 is —SO3M, or —SO2NH2; R2 is C1-6 alkyl or C1-6 alkylamine; and M is a monovalent cation selected from the group consisting of lithium, sodium, potassium, and ammonium. Also encompasses herein are methods of identifying and treating a subject having or suspected of having osteoarthritis.

Abstract: The present disclosure relates to an ?-fucosidase having ?-(1,2), ?-(1,3), ?-(1,4), and ?-(1,6) fucosidase activity. The present disclosure also relates to the compositions comprising the ?-fucosidase, and the methods of producing and using the ?-fucosidase in cleaving ?-(1,2), ?-(1,3), ?-(1,4), and/or ?-(1,6)-linked fucoses in the glycoconjugates.

Abstract: Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of the present disclosure may be used as a dietary supplement for the prophylaxis or treatment of amyloid related neurodegenerative diseases so as to ameliorate or alleviate symptoms associated with the amyloid related neurodegenerative diseases.

Abstract: The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The compositions of the invention provide virus-like particles (VLPs) whose effectiveness is enhanced by the selection of preferred adjuvants.

Abstract: The present disclosure relates to transgenic plants that over-express PP2CABA and methods of using such for enhancing osmotic stress tolerance.

Abstract: Disclosed herein are methods and apparatus for reducing errors in spectroscopic measurements. The present method minimizes errors by aligning peak positions and recalculating intensities in every single-scan spectrum with reference to spectral features observed in the spectrum integrating all uncorrected single-scan spectra. Additionally, the corrected single-scan spectra are integrated to improve the resolving power, signal intensity and peak shape.

Abstract: Provided herein is a novel antibody exhibiting binding affinity and specificity to galectin-7. Also provided herein are methods for treating psoriasis or cancer in a subject by administering to the subject a drug selected with the aid of the present anti-galectin-7 antibody.

Abstract: The present invention relates to a method for regulating potency of pluripotent stem cells (PSCs) by modulating expression of podocalyxin-like protein 1 (PODXL) and applications thereof.

Abstract: The invention found that first, the feasibility of transfer of tumor resistance and other healthy longevity characters through transplantation of bone marrow mononuclear cells (BMMNC) or hematopoietic stem cells (HSC)/hematopoietic stem and progenitor cells (HSPC) consisting of genetically engineered EKLF gene encoding the hematopoietic transcription factor EKLF. Secondly, the present invention demonstrates expression of EKLF in the long-term hematopoietic stem cells (LT-HSC), and thus EKLF as a target of regulation of hematopoiesis.

Abstract: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.

Abstract: A microscope-based system and a method for image-guided microscopic illumination are provided. The microscope-based system for image-guided microscopic illumination comprises a microscope, an illuminating assembly, an imaging assembly, a first processing module, and a second processing module. The microscope comprises a stage, and the stage is configured to be loaded with a sample. The imaging assembly comprises a camera. The processing modules are coupled to the microscope, the imaging assembly, and the illuminating assembly.

Abstract: Disclosed herein are recombinant proteins including an IGFBP3 or a biologically active fragment thereof and an IgG Fc portion linked to the C-terminus of the IGFBP3 variant. The recombinant proteins including at least one additional domain of other growth factors are also disclosed. Methods for treating tumors, in particular, tumors resistant to the targeted therapy, using the above-mentioned recombinant proteins are also provided.

Abstract: A genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.

Abstract: Methods for ameliorating cardiac is juries such as myocardial infarction by either enhancing the activity of a let-7 microRNA or inhibiting the activity of transformation growth factor beta receptor III (T GFBR3). Also provided herein are assay methods for detecting the level of TGFBR3, the level of a let-7 microRNA, or both in a biological sample.

Abstract: A harmonic light-generating metasurface includes a base substrate and a plurality of structures, that include nonlinear material, that are disposed in a pattern on a surface of the base substrate. Each structure of the plurality of structures individually supports a magnetic dipole mode. An electromagnetic field enhancement of the magnetic dipole mode induces generation of a harmonic signal by the plurality of structures. Alternatively, a harmonic light-generating metasurface, includes a base substrate, a supporting substrate that includes a nonlinear material, and a plurality of paired structures disposed in a pattern on a surface of the supporting substrate. Each paired structure, of the plurality of paired structures, collectively supports a toroidal dipole mode. An electromagnetic field enhancement of the toroidal dipole mode penetrates the supporting substrate to induce generation of a harmonic signal by the supporting substrate.

Abstract: Provided herein is a method for treating a subject afflicted with a metastatic cancer. The method includes, administering to the subject an effective amount of an agent capable of suppressing the expression of a nucleic of EF-hand domain-containing protein D2 (EFHD2) or a polypeptide encoded by the nucleic acid in the metastatic cancer of the subject. The agent may be a 2-aryl propionic acid (2-APA) compound, or a short hairpin ribonucleic acid (shRNA) that directs cleavage of EFHD2 gene RNA via RNA interference. Also provided herein is a method for detecting and/or diagnosing whether a subject having a metastatic cancer via a biological sample of the subject.

Abstract: The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.

Abstract: A method for suppressing tumor metastasis, in which an effective amount of a compound of formula (I) is administered to a subject in need thereof. Also disclosed is a method of treating cancer, in which an effective amount of a chemotherapy agent and an effective amount of a compound of formula (I) is administered to a subject in need thereof. Further disclosed are pharmaceutical compositions for suppressing tumor metastasis and for treating cancer, each of the compositions containing a compound of formula (I).